Drug Trial Radar · NCT07311993
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Feb 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Cellectar Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are: * What dose and regimen should be used in future trials of CLR 125 in patients with advanced triple negative breast cancer. * What side effects do participants have when taking CLR 125. Participants will: * Have CLR 125 administered via infusion 4 times each cycle; repeated every 8 weeks. * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or new medications. Some participants may also receive one dose of CLR 131 to evaluate the amount of radiation delivered to various organs and to the tumor. These participants will: * Have 4 scans completed over 2 weeks * Have blood drawn 6 times over 2 weeks.
Conditions
- Breast Cancer
Interventions
Iopofosine I 131Drug
Investigational radiopharmaceutical product intended for IV administration.
CLR 125Drug
Investigational radiopharmaceutical product intended for IV administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Determination for CLR 125Time frame: 57 days after initiation of last cycle (each cycle is 57 days)
- Number of adverse events related to study treatment (CLR 125)Time frame: Assessed throughout the study through 1 year following completion of treatment.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Florida
Jacksonville, Florida · Recruiting
United Theranostics
Glen Burnie, Maryland · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
United Theranostics
Princeton, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.